Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An EZB diffuse large B-cell lymphoma that expresses the double hit gene expression signature (DHITsig+) according to gene expression profiling. In addition to the features characteristic of EZB, these cases commonly, but do not always, harbour MYC translocations and DDX3X mutations.
Biomarker and diagnostic research for EZB-MYC+ diffuse large B-cell lymphoma has been reported in the published literature.
No clinical trials have been registered for EZB-MYC+ diffuse large B-cell lymphoma.
3 publications have been identified in PubMed for EZB-MYC+ diffuse large B-cell lymphoma. Research spans Diagnostic / Biomarker (67%) and Basic Science / Preclinical (33%).
Yim J (2026). [PMID: 41544233](https://pubmed.ncbi.nlm.nih.gov/41544233/). *Blood Adv*. [Diagnostic / Biomarker]
Pomares AA (2025). [PMID: 40067847](https://pubmed.ncbi.nlm.nih.gov/40067847/). *PLoS One*. [Basic Science / Preclinical]
Wang Y (2025). [PMID: 41260205](https://pubmed.ncbi.nlm.nih.gov/41260205/). *Cell Rep Med*. [Diagnostic / Biomarker]
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 2:39 AM UTC
Common questions about EZB-MYC+ diffuse large B-cell lymphoma